Trump wants a vaccine by end of this year but the barriers are too high

The Trump administration has set sail on one of the most ambitious vaccine development efforts in history.
Every effort to develop a new medicine is like launching a ship across the ocean to hunt for riches. Over the years, we’ve improved the hulls and masts, the maps are better, the sailors more experienced. But even so, vessels get turned back or new lands are barren. And, sometimes, a squall takes down the boat and all her crew.

 
The Trump administration has set sail on one of the most ambitious vaccine development efforts in history. Operation Warp Speed is likely to deliver a Covid-19 inoculation in a fraction of the years it would usually take. If it does so, it could save the lives of hundreds of thousands of people and economies around the world.

But the administration has also offered timelines for a vaccine that fly in the face of almost every experience in pharmaceutical history. On Tuesday night, President Donald Trump said a shot could be ready in three or four weeks. Then, on Wednesday, Paul Mango, deputy chief of staff for policy at the Department of Health and Human Services and one of the senior leaders of the Warp Speed program, said every American could be vaccinated by the end of March.

Mango said that there are enough doses in production and that trials are moving at a speed so that “the combination of those two will permit us to vaccinate every American before the end of first quarter 2021.” A few hours later, White House Press Secretary Kayleigh McEnany said that “we do believe that it will be widely available by the end of” this year, though also referred to doses of the vaccine being production by then, as opposed to actually distributed. 

Mango’s and McEnany ’s remarks were contradicted by the head of the Centers for Disease Control Prevention, Director Robert Redfield, who told Congress Wednesday that it would likely take until late spring or the summer of next year for most Americans to have access to a vaccine. Other top U.S. health officials have said it’s not likely a vaccine will be ready until the end of the year, and that expanding access to the more than 300 million people living in the U.S. will take longer.

“It would be aspirational to do that,” said Anthony Fauci, the head of the National Institute for Allergy and Infectious Diseases. “But I think it’s more toward the middle to the end of the year that you can get people vaccinated. It depends on what the vaccine is.”

The U.S. has launched many ships. Pfizer Inc., Moderna Inc. and AstraZeneca Plc have headed out at a rapid clip. The early data look promising, and late-stage trials in tens of thousands of volunteers could produce a rapid answer.

But to deploy a vaccine widely by early next year, it’s worth keeping in mind what has to go right:

  • One of the vaccines has to work.
  • The vaccine that works has to be one of the handful that are already in late-stage trials.
  • There can’t be a major safety concern or delay.
  • The clinical trials have to generate strong evidence.
  • The FDA has to accept that evidence and review it rapidly.
  • The manufacturing has to go near perfectly.
  • Hundreds of millions of doses must be delivered around the country, likely with some degree of low-temperature storage requirements.

Even in vaccination efforts that the U.S. runs every year, it’s hard to meet the goal of wide uptake. For the 2017-2018 flu season, only 37% of Americans actually got a vaccine, according to the CDC. Many people get it at work, at school, at a drugstores or in hospitals --places that are largely closed or that many Americans are avoiding because of the pandemic.

There are a few loosely understood rules of running a pharmaceutical company, outside the necessity of making a reasonable return for shareholders.

A first rule is don’t kill anyone. A second one is to help people live longer, better lives. The third is not to get sued by securities regulators.

It’s a simple set of goals that often runs into the brutal reality of drug development, often summed up by insiders with the oft-repeated pearl, “science is hard.” Every year, the pharmaceutical industry spends billions on failure. Drugs seem like miracles, then turn out to be a mirage. Much of the money companies invest in research goes toward projects that are stopped because they either don’t help people or might hurt them.

The result is that most companies -- there are, of course, exceptions -- are conservative in their pronouncements. And some have been preparing for a vaccine. Merck & Co. has been quietly betting that the first shot across the line won’t necessarily be the best, and that its experimental vaccine could top the early winners. Some form of vaccine is likely to be needed for years, as well, leaving plenty of room for incremental improvements like better protection, more durable immunity, and more certain safety.

To that end, earlier this month, the National Academies of Sciences, Engineering, and Medicine published a report summarizing expert recommendations for distributing a Covid-19 vaccine.

On page 11, it cites a key lesson from past mass vaccination efforts: “Under-promise and over-deliver.”

Having violated the first half of that advice, the best hope now is that the U.S. delivers on the second.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel